Abstract
A novel multi-cancer early detection (MCED) test can screen for multiple types of cancer via a single blood draw. This screening test could be implemented in a broad segment of the population. As with any screening, there is potential for false positive (FP) Results: Economic modeling to assess the value of incorporating MCED testing with conventional cancer screening would need to consider the impact of FPs. The purpose of this study was to pilot-test health state vignettes and procedures that could be used to estimate the disutility (i.e., decrease in health state utility) associated with FPs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
